

Olga Martinho

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3937809/olga-martinho-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

46
papers

1,343
citations

22
h-index

35
g-index

54
ext. papers

1,524
ext. citations

4.2
avg, IF

3.95
L-index

| # | Paper | IF | Citations |
|----|--|------|-----------|
| 46 | Implications of RKIP protein in cancer prognosis and therapy response: A literature update 2020 , 389-414 | | |
| 45 | Magnetoliposomes Containing Calcium Ferrite Nanoparticles for Applications in Breast Cancer Therapy. <i>Pharmaceutics</i> , 2019 , 11, | 6.4 | 18 |
| 44 | Modified ingenol semi-synthetic derivatives from Euphorbia tirucalli induce cytotoxicity on a large panel of human cancer cell lines. <i>Investigational New Drugs</i> , 2019 , 37, 1029-1035 | 4.3 | 6 |
| 43 | Current Status of Raf Kinase Inhibitor Protein (RKIP) in Lung Cancer: Behind RTK Signaling. <i>Cells</i> , 2019 , 8, | 7.9 | 14 |
| 42 | Euphol, a tetracyclic triterpene, from Euphorbia tirucalli induces autophagy and sensitizes temozolomide cytotoxicity on glioblastoma cells. <i>Investigational New Drugs</i> , 2019 , 37, 223-237 | 4.3 | 22 |
| 41 | RKIP as an Inflammatory and Immune System Modulator: Implications in Cancer. <i>Biomolecules</i> , 2019 , 9, | 5.9 | 7 |
| 40 | Semi-Synthetic Ingenol Derivative from Euphorbia tirucalli Inhibits Protein Kinase C Isoforms and Promotes Autophagy and S-phase Arrest on Glioma Cell Lines. <i>Molecules</i> , 2019 , 24, | 4.8 | 3 |
| 39 | Hexane partition from Annona crassiflora Mart. promotes cytotoxicity and apoptosis on human cervical cancer cell lines. <i>Investigational New Drugs</i> , 2019 , 37, 602-615 | 4.3 | 9 |
| 38 | In vitro screening of cytotoxic activity of euphol from Euphorbia tirucalli on a large panel of human cancer-derived cell lines. <i>Experimental and Therapeutic Medicine</i> , 2018 , 16, 557-566 | 2.1 | 13 |
| 37 | HER Family Receptors are Important Theranostic Biomarkers for Cervical Cancer: Blocking Glucose Metabolism Enhances the Therapeutic Effect of HER Inhibitors. <i>Theranostics</i> , 2017 , 7, 717-732 | 12.1 | 25 |
| 36 | Metabolic alterations underlying Bevacizumab therapy in glioblastoma cells. <i>Oncotarget</i> , 2017 , 8, 103657-103670 | 3.1 | 10 |
| 35 | Monocarboxylate transporter 1 is a key player in glioma-endothelial cell crosstalk. <i>Molecular Carcinogenesis</i> , 2017 , 56, 2630-2642 | 5 | 24 |
| 34 | Serotonin regulates prostate growth through androgen receptor modulation. <i>Scientific Reports</i> , 2017 , 7, 15428 | 4.9 | 14 |
| 33 | AKT can modulate the response of HNSCC cells to irreversible EGFR inhibitors. <i>Oncotarget</i> , 2017 , 8, 53288-53301 | 3.3 | 10 |
| 32 | Molecular characterization of short-term primary cultures and comparison with corresponding tumor tissue of Brazilian glioblastoma patients. <i>Translational Cancer Research</i> , 2017 , 6, 332-345 | 0.3 | 5 |
| 31 | Raf Kinase Inhibitor Protein Expression and Prognostic Value in Soft Tissue Sarcomas. <i>Pathobiology</i> , 2016 , 83, 41-6 | 3.6 | 5 |
| 30 | Cytotoxicity of allitinib, an irreversible anti-EGFR agent, in a large panel of human cancer-derived cell lines: KRAS mutation status as a predictive biomarker. <i>Cellular Oncology (Dordrecht)</i> , 2016 , 39, 253-63 | 7.2 | 25 |

| | | | |
|----|--|-----|-----|
| 29 | Hypoxia-mediated upregulation of MCT1 expression supports the glycolytic phenotype of glioblastomas. <i>Oncotarget</i> , 2016 , 7, 46335-46353 | 3.3 | 62 |
| 28 | Molecular profiling, including TERT promoter mutations, of acral lentiginous melanomas. <i>Melanoma Research</i> , 2016 , 26, 93-9 | 3.3 | 42 |
| 27 | In vitro and in vivo studies of temozolomide loading in zeolite structures as drug delivery systems for glioblastoma. <i>RSC Advances</i> , 2015 , 5, 28219-28227 | 3.7 | 17 |
| 26 | AXL as a modulator of sunitinib response in glioblastoma cell lines. <i>Experimental Cell Research</i> , 2015 , 332, 1-10 | 4.2 | 25 |
| 25 | Silencing of the tumor suppressor gene WNK2 is associated with upregulation of MMP2 and JNK in gliomas. <i>Oncotarget</i> , 2015 , 6, 1422-34 | 3.3 | 17 |
| 24 | Glucose Addiction in Cancer Therapy: Advances and Drawbacks. <i>Current Drug Metabolism</i> , 2015 , 16, 221-42 | 3.5 | 44 |
| 23 | Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets. <i>Neuro-Oncology</i> , 2013 , 15, 172-88 | 1 | 162 |
| 22 | Loss of WNK2 expression by promoter gene methylation occurs in adult gliomas and triggers Rac1-mediated tumour cell invasiveness. <i>Human Molecular Genetics</i> , 2013 , 22, 84-95 | 5.6 | 38 |
| 21 | In Vitro and In Vivo Analysis of RTK Inhibitor Efficacy and Identification of Its Novel Targets in Glioblastomas. <i>Translational Oncology</i> , 2013 , 6, 187-96 | 4.9 | 49 |
| 20 | Low RKIP expression associates with poor prognosis in bladder cancer patients. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013 , 462, 445-53 | 5.1 | 15 |
| 19 | Absence of RKIP expression is an independent prognostic biomarker for gastric cancer patients. <i>Oncology Reports</i> , 2013 , 29, 690-6 | 3.5 | 18 |
| 18 | RKIP inhibition in cervical cancer is associated with higher tumor aggressive behavior and resistance to cisplatin therapy. <i>PLoS ONE</i> , 2013 , 8, e59104 | 3.7 | 44 |
| 17 | Analysis of a synchronous gliosarcoma and meningioma with long survival: A case report and review of the literature. <i>Surgical Neurology International</i> , 2013 , 4, 151 | 1 | 3 |
| 16 | Loss of RKIP expression during the carcinogenic evolution of endometrial cancer. <i>Journal of Clinical Pathology</i> , 2012 , 65, 122-8 | 3.9 | 21 |
| 15 | Involvement of signaling molecules in the prediction of response to imatinib treatment in metastatic GIST patients. <i>Journal of Surgical Research</i> , 2012 , 178, 288-93 | 2.5 | 12 |
| 14 | Zeolite Structures Loading with an Anticancer Compound As Drug Delivery Systems. <i>Journal of Physical Chemistry C</i> , 2012 , 116, 25642-25650 | 3.8 | 100 |
| 13 | Downregulation of RKIP is associated with poor outcome and malignant progression in gliomas. <i>PLoS ONE</i> , 2012 , 7, e30769 | 3.7 | 46 |
| 12 | Co-expression of monocarboxylate transporter 1 (MCT1) and its chaperone (CD147) is associated with low survival in patients with gastrointestinal stromal tumors (GISTs). <i>Journal of Bioenergetics and Biomembranes</i> , 2012 , 44, 171-8 | 3.7 | 44 |

| | | | |
|----|---|-----|----|
| 11 | Encapsulation of Cyano-4-hydroxycinnamic acid into a NaY zeolite. <i>Journal of Materials Science</i> , 2011 , 46, 7511-7516 | 4.3 | 31 |
| 10 | Malignant Gliomas: Role of Platelet-Derived Growth Factor Receptor A (PDGFRA) 2011 , 109-118 | | 1 |
| 9 | Lymphangiogenic VEGF-C and VEGFR-3 expression in genetically characterised gastrointestinal stromal tumours. <i>Histology and Histopathology</i> , 2011 , 26, 1499-507 | 1.4 | 9 |
| 8 | Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: a Portuguese multicentre study. <i>Oncology Reports</i> , 2010 , 23, 1655-62 | 3.5 | 43 |
| 7 | Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas. <i>British Journal of Cancer</i> , 2009 , 101, 973-82 | 8.7 | 87 |
| 6 | Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma. <i>BMC Cancer</i> , 2009 , 9, 212 | 4.8 | 42 |
| 5 | Loss of RKIP expression is associated with poor survival in GISTs. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2009 , 455, 277-84 | 5.1 | 51 |
| 4 | Low frequency of MAP kinase pathway alterations in KIT and PDGFRA wild-type GISTs. <i>Histopathology</i> , 2009 , 55, 53-62 | 7.3 | 35 |
| 3 | A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours. <i>European Journal of Cancer</i> , 2009 , 45, 2352-9 | 7.5 | 26 |
| 2 | KIT activation in uterine cervix adenosquamous carcinomas by KIT/SCF autocrine/paracrine stimulation loops. <i>Gynecologic Oncology</i> , 2008 , 111, 350-5 | 4.9 | 14 |
| 1 | Molecular alterations of KIT oncogene in gliomas. <i>Analytical Cellular Pathology</i> , 2007 , 29, 399-408 | 3.4 | 17 |